Fundraising FoxHBM Partners
Venture capitalZug · Pre-Seed–Late Stage · 6 people tracked
Find your way into HBM Partners
394 people in our graph share verified history with the HBM Partners team — schools, employers, funds. One of them is your warm intro.
Investment thesis
HBM Partners invests in private and public healthcare companies spanning biopharma, medtech, diagnostics and broader healthcare, backing venture, growth and buy-out financings. The firm targets companies in Europe, North America, India, China and other emerging markets, typically writing checks of USD 5 to 50 million. Regulated by FINMA, it advises the SIX-listed HBM Healthcare Investments Ltd along with several specialised public and private equity funds. HBM emphasizes adding value by leveraging deep sector experience and a worldwide industry network to source, analyse and support investments, with a track record of over 100 investments producing more than 60 trade sales and IPOs.
Source: firm website, verified Sep 27, 2026.
Team · 6 people
from the firm's website & curated & public directories
Founder mafia
2 people who came through HBM Partners went on to found or lead other companies.
What they invest in
from 33 of 49 portfolio companiesHealthtech ×28Biotech ×27Medical Devices ×15AI & Machine Learning ×7Digital Health ×7Deep Tech ×5E-commerce ×2B2B Marketplaces ×1
HQs:United States×24Germany×2Switzerland×1China×1India×1Italy×1
Investments · 49 tracked
founders shown can be your intro pathBy year:2025 · 12022 · 42021 · 22020 · 42017 · 12016 · 12015 · 114 dated
Monte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets.
AI & Machine LearningBiotechDeep TechHealthtechBoston, US
Markus Warmuth(M.D., Chief Executive Officer)inSharon Townson(Ph.D., Chief Scientific Officer)inJohn Castle(Ph.D., Chief Data and Information Officer)inFilip Janku(M.D., Ph.D., Chief Medical Officer)inPhil Nickson(Ph.D., J.D., Chief Business and Legal Officer)inMagnus Walter(DPhil, Chief Technology Officer)in
Co-investorsAisling CapitalNew Enterprise Associates (NEA)Versant VenturesAmzak HealthAvoro Capital AdvisorsGV (Google Ventures)+2 more
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)inMark Bradley(Chief Development Officer)inKolbot By(SVP, Head of Technical Operations)inJack Danilkowicz(Chief Commercial Officer)inJörn Drappa(Chief Medical Officer)inDavid M Goldstein(Chief Scientific Officer)in
Co-investorsForesite CapitalHBM Healthcare InvestmentsNextech InvestOrbiMedSamsara BioCapitalSR One Capital Management+3 more
ALX Oncology develops therapies for cancer treatment, operating in the biotechnology and medical technology sectors.
BiotechHealthtechMedical Devices
Corey Goodman(Chairman)inJason Lettmann(Chief Executive Officer)in
Co-investorsLightstone Venturesage1Foresite CapitalHBM Healthcare InvestmentsvenBio PartnersLogos+1 more
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon, US
Riley Ennis(Co-Founder and Chief Product Officer)inCharles Roberts(Director)inGabriel Otte(Director)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)
Co-investorsRA CapitalAgent CapitalAME Cloud VenturesAndreessen HorowitzArtis VenturesAsset Management Company+12 more
Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases.
BiotechHealthtechMedical DevicesNorthbrook, US
Jeffrey Aronin(Director)inJeffrey M. Dayno, M.D.(President and Chief Executive Officer)inPatrick Morris(Secretary and Treasurer)inRobert Repella(Director and Chief Executive Officer)Darien Parhad(Chief Financial Officer)
BoardAaron Royston(Director)in
Co-investorsAisling CapitalHBM Healthcare InvestmentsParagon Biosciences LLCPivotal Life SciencesValor Equity PartnersvenBio Partners+3 more
Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.
BiotechHealthtechRadnor, US
Eric Warren(Chief Commercial Officer)inAlex Gold(Chief Medical Officer)inAdam Levy(Executive Officer)Alexander Asam(Director)
BoardBrian Taylor Slingsby(Founder & former CEO / Board Director)Olivier Litzka(Director)in
Co-investorsAndera PartnersHBM Healthcare InvestmentsSamsara BioCapitalSR One Capital ManagementYsios CapitalAdams Street Partners+3 more
Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.
BiotechHealthtechWaltham, US
Rand Sutherland(Chief Executive Officer)inAllison Ambrose(General Counsel)inAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)Adam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in
Co-investorsOrbiMedAccess IndustriesAccess BiotechnologyBain Capital Life SciencesDecheng CapitalHBM Healthcare Investments+4 more
Swixx BioPharma is a specialized pharmaceutical distributor and market access partner that represents international biopharma, OTC, and medical device companies in markets across Central & Eastern Europe, the Middle East, North Africa, Latin America, and Eurasia.
BiotechHealthtechMedical DevicesBaar, CH
Co-investorsBain Capital Life SciencesMérieux Equity PartnersSK Capital PartnersHBM Healthcare Investments
1000Farmacie is an Italian online pharmacy and parapharmacy marketplace that aggregates products from over 60 partner pharmacies and other sellers, offering over 100,000 products for health and wellness including pharmaceuticals, medical devices, veterinary medicines, homeopathic and ayurvedic products, with home delivery across Italy.
B2B MarketplacesE-commerceHealthtechItaly, IT
Nicolo Petrone(Founder)inAlberto Marchetti(Founder)in
Co-investorsClub degli InvestitoriHBM Healthcare InvestmentsItalian Angels for GrowthLIFTTP101 Ventures
This is a product listing page on an online pharmacy for Tugain Twins 5 Solution, a topical minoxidil-based medicine sold to treat hair loss and promote hair regrowth.
Digital HealthE-commerceHealthtechIndia, IN
Co-investorsHBM Healthcare InvestmentsKae CapitalLeo Capital VenturesPeak XV PartnersSpring Marketing CapitalVenturEast+3 more
AdrenoMed AG is a clinical-stage biopharmaceutical company developing Enibarcimab (formerly Adrecizumab), a first-in-class antibody targeting the peptide Adrenomedullin to restore vascular integrity in critically ill patients, with septic shock as its lead indication.
BiotechHealthtechMedical DevicesHennigsdorf, DE
Gerald Moeller(Co-founder and former CEO of AdrenoMed; Supervisory Board member)inRichard Jones(Chief Executive Officer (CEO))inDavid Germonpré(Chief Financial Officer (CFO))in
Co-investorsBrandenburg KapitalCatalyze CapitalHBM Healthcare InvestmentsVU Venture Partners
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.
BiotechFemTechHealthtechMedical DevicesRedwood City, US
Karl Y. Hostetler(Executive Officer, Director)inGail Maderis(Director)inKristine Ball(President & CEO)inElaine Chien(Executive Officer)inSarah Walter(Executive Officer)inRaju Gadiraju(Executive Officer)in
Co-investorsAdjuvant CapitalAvestria VenturesBrace PharmaCanaan PartnersGV (Google Ventures)HBM Healthcare Investments+6 more
Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Michael Gilman(Executive Officer, Director)inMark DeLong(CEO)inDavid Neafus(Executive Officer)inRussell C. Petter(Executive Officer)
BoardColleen Cuffaro(Director)inAlan E. Walts(Director)in
%20copy.jpg)
Co-investorsCanaan PartnersPfizer VenturesAdvent Life SciencesHBM Healthcare InvestmentsNextech InvestOUP (Osage University Partners)+3 more
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.
BiotechHealthtechMedical DevicesNewtown Square, US
Zhengbin (Bing) Yao(Executive Officer, Director)inBrent Rice(Chief Commercial Officer)in
BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)
Co-investorsCatalio Capital Management, LPForesite CapitalGeneral CatalystHBM Healthcare InvestmentsHongShan Capital GroupLAV+4 more
.png)
CellCentric develops inobrodib, a small-molecule oral p300/CBP inhibitor intended to treat multiple myeloma and other cancers.
BiotechHealthtechMedical Devices
Azim Surani(Co-founder)
Co-investorsAvego BioScience CapitalFuture Planet CapitalHBM Healthcare InvestmentsRA CapitalBrightEdgeForbion+1 more
connectRN operates a mobile app marketplace that matches nurses and clinicians with open shifts at healthcare facilities such as hospitals, home health, and hospice across the US.
Future of WorkHealthtechHR TechMarketplacesWaltham, US
Ted Jeanloz(Executive Officer)in
BoardMichael Jasulavic(Director)John Pappajohn(Director)Geoffrey Harris(Director)Idriz Limaj(Director)
Co-investorsData Point CapitalHBM Healthcare Investments
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Chief Executive Officer, Founder)
BoardIvan Trifunovich(Director)John Wesley(Director)
Co-investors8VCAisling CapitalHBM Healthcare InvestmentsMission Bay CapitalMission BiocapitalOlive Tree Capital+4 more
Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.
BiotechBrookline, US
Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)
BoardGeorge M. Church(Director)
Co-investorsAlta PartnersARCH Venture PartnersCatalio Capital Management, LPHBM Healthcare InvestmentsKhosla VenturesLifeSci Venture Partners+13 more
Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Adam Rosenthal(Co-founder and former CEO; Director)inQuehuong (Kathy) Dong, Pharm.D.(Executive Officer, Director)Kathy Dong(President, Chief Executive Officer and Director)in
BoardBeth Seidenberg, M.D.(Director)Thomas Geninatti, Ph.D.(Director)Carl Gordon, Ph.D.(Director)
Co-investorsHBM Healthcare InvestmentsOrbiMedRA CapitalWestlake Village BioPartnersKleiner PerkinsNVIDIA
Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.
BiotechHealthtechMedical DevicesPhiladelphia, US
Co-investorsHBM Healthcare InvestmentsLG Technology VenturesNovartis Venture FundOrbiMedPontifax Venture CapitalSR One Capital Management+3 more
Genalyte develops Merlin, a real-time diagnostic system that performs laboratory testing directly in clinical settings and integrates results with electronic health records.
Digital HealthHardwareHealthtechMedical DevicesSan Diego, US
Cary Gunn(Co-founder and Chief Technical Officer)in
Co-investorsBioBritBoutique Venture PartnersClaremont Creek VenturesFusionX VenturesHBM Healthcare InvestmentsIPD Capital+6 more
Karius is a company that provides microbial cell-free DNA (mcfDNA) metagenomic sequencing services for research and clinical applications.
AI & Machine LearningBiotechDigital HealthMedical DevicesSan Francisco, US
Alec Ford(Chief Executive Officer)in
Co-investors5AM VenturesDCVC (Data Collective)HBM Healthcare InvestmentsKhosla VenturesLightspeed Venture PartnersSeventure Partners+1 more
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Carolyn Bertozzi(Lycia founder and Professor of Chemistry, Stanford University)inAetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)in
Co-investorsREDMILEVersant VenturesHBM Healthcare InvestmentsBAM ElevateFranklin TempletonInvus+5 more
Mahzi develops therapies for patients with under-diagnosed and under-served rare genetic neurodevelopmental disorders, working with patient and family groups, academic researchers, and industry partners.
BiotechHealthtechSouth San Francisco, US
Yael Weiss(Executive Officer, Director)in
BoardCamille Samuels(Director)inMarten Steen(Director)inShalini Sharp(Director)inStephen Farr(Director)
Co-investorsDroia VenturesHBM Healthcare InvestmentsHealthCapMitsui Global InvestmentVenrockVenrock Associates
Neurelis is a neuroscience-based biopharmaceutical company that develops treatments for people living with neurological conditions such as epilepsy.
BiotechHealthtechMedical DevicesEncinitas, US
Craig C. Chambliss(Executive Officer, Director)inCraig Chambliss(Founder)in
BoardDavid F. Hale(Director)Cam Garner(Director)Yong Zhang(Director)Kevin Li(Director)in
Co-investorsHBM Healthcare InvestmentsLYZZ CapitalOrbiMed
Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease.
AI & Machine LearningBiotechDeep TechDigital HealthSouth San Francisco, US
Nancy Stagliano(CEO)in
Co-investorsHBM Healthcare InvestmentsKleiner PerkinsSoftBank GroupSoftBank Vision FundWestlake Village BioPartnersACORN BIOVENTURES+2 more
NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2.
BiotechHealthtechWilmington, CN
Yan Lou(Founder)inZhenhai Gao(President, CEO, and Secretary)Hong (Kelsey) Chen(Chief Financial Officer)
BoardGary Yeung(Director)Ting Jia(Director)Roderick Wong(Director)
Co-investorsEcoR1 CapitalHBM Healthcare InvestmentsLAVLilly Asia VenturesRA CapitalSamsara BioCapital+2 more
Numab develops multispecific antibody-based therapeutics using its proprietary λ-Cap and MATCH discovery and engineering platforms, aiming to improve on first-generation antibody therapies in potency, stability, effect duration, and safety.
BiotechDeep Tech
David Urech(Founder)in
Co-investorsEisai Innovation, Inc.HBM Healthcare InvestmentsBiotechnology Value FundBlackRockForbionNovo Holdings+1 more
Shape Memory Medical develops embolization and occlusion medical devices built on a bioabsorbable shape memory ("smart") polymer that expands to conform to vascular anatomy.
HealthtechSan Jose, US
Duncan Maitland(Director)inMichael Henson(Executive Officer, Director)inEdward F. Ruppel, Jr(Executive Officer, Director)Carolyn M. Bruguera(Executive Officer)James Y Lancaster(Executive Officer, Director)in
BoardThom Rasche(Director)
Co-investorsEmergent Medical Partners, LLPHBM Healthcare InvestmentsEarlybird Venture CapitalTaiwania Capital
SphingoTec develops proprietary biomarkers for critical care diagnostics, addressing acute kidney injury, sepsis, and acute heart failure through partnerships with in vitro diagnostics companies and pharmaceutical firms.
BiotechDeep TechDigital HealthHealthtechMedical DevicesHennigsdorf, DE
Deborah Bergmann(Chief Executive Officer)in
Co-investorsBrandenburg KapitalHBM Healthcare Investments
Co-investorsForesite CapitalLAVLilly Asia VenturesNextech InvestSv Tech Ventures, Inc.SR One Capital Management
Valo Health applies technology and data to drug discovery, working across the technology, biotech, and healthcare fields.
AI & Machine LearningBiotechHealthtech
David Berry(Founder)in
Co-investorsAtinum Investment Co. Ltd.BioGenerator VenturesFlagship PioneeringHBM Healthcare InvestmentsKoch Disruptive Technologies
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
ADARxC-Ray TherapeuticsCathay Biotech Inc.CORXEL PharmaceuticalsCrystlaysCure Everlife HoldingsFangzhou / JiankeFarmalatamIgnis TherapeuticsiTeos TherapeuticsNuance BiotechOnesourceRiver RenalSwixx HealthcareSymbiomix TherapeuticsVascular DynamicsVisen Pharma
Exits · 8
7 IPOs · 1 acquisitions · showing 7Monte Rosa TherapeuticsNASDAQ: GLUEAlumisNASDAQ: ALMSAlx OncologyNASDAQ: ALXOFreenomeNASDAQ: FRNMHarmony BiosciencesNASDAQ: HRMYMineralys TherapeuticsNASDAQ: MLYSUpstream BioNASDAQ: UPB
Portfolio news
latest coverage across their companiesFore Biotherapeutics · finsmes.com · Jul 8, 2026
Lycia Therapeutics · finsmes.com · Jun 29, 2026
Arrakis Therapeutics · biospace.com · Jun 25, 2026
CellCentric · finsmes.com · May 6, 2026
Dren Bio · biospace.com · Mar 2, 2026
Neuron23 · finsmes.com · Jun 25, 2025
Frequently asked questions
- How many investments has HBM Partners made?
- HBM Partners has 49 tracked investments, 8 of which have exited, including 1 dated in the last 24 months.
- What stage does HBM Partners invest at?
- HBM Partners invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is HBM Partners's typical check size?
- HBM Partners typically writes checks of $5M – $50M.
- What sectors does HBM Partners focus on?
- HBM Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is HBM Partners located?
- HBM Partners is headquartered in Zug, CH.
Co-investors · 8
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
SR One Capital Management is a life sciences venture capital firm that takes a 'back-and-build' approach, providing entrepreneurs with human, intellectual, and financial resources. It emerged from the legacy SR One team formerly part of GSK.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.
Lilly Asia Ventures (LAV) is a biomedical venture capital firm with offices in Hong Kong, Shanghai, and Palo Alto, backing entrepreneurs building companies focused on breakthrough products that treat disease and improve human health.
Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Pontifax is a venture capital firm focused on life sciences and healthcare technologies, investing across all development stages from early-stage startups to clinical-stage growth companies.
Firms observed investing alongside HBM Partners, from public investor directories. Shared companies are the overlap with HBM Partners's recorded portfolio.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Menlo Ventures is an early-stage venture capital firm backing transformative technology companies, with a strong current emphasis on artificial intelligence across enterprise, healthcare, and consumer markets.